MRK  Merck & Company Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

+0.09 (+0.16%)

Growth Price

Overvalued by 40.21%

Stability Price

Overvalued by 65.46%

Company Metrics

  • 14.15 P/E
  • 3.86 P/S
  • 3.36 P/B
  • 4.07 EPS
  • 12.10% Cash ROIC
  • 0.84 Cash Ratio
  • 1.8 / 3.1% Dividend
  • 11.04M Avg. Vol.
  • 163.48B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Merck & Co., Inc. Seeks FDA Approval As Keytruda Is Shown To Shrink Lung ...
Bidness ETC - Apr 20, 2015
Merck & Co., Inc. (NYSE:MRK) announced that it has submitted an application to the US Food and Drug Administration (FDA) seeking approval for its cancer drug Keytruda, to treat patients with non-small cell lung cancer (NSCLC), after a study comparing ...
Merck & Co. Seek FDA Approval for Melanoma Drug Keytruda - Healthcare Global
Test May Show Merck Melanoma Drug's Success in Lung Cancer - Bloomberg
Sell-Side Research Consensus on Merck & Company, Inc. (NYSE:MRK)
The Markets Daily - 23 hours ago
On a consensus basis, Street analysts are expecting Merck & Company, Inc. (NYSE:MRK) to report earnings per share of $0.75 for the quarter ending 2015-03-31.
Stock Update: Merck & Co Inc (NYSE:MRK) - Merck Announces Results from C ... - Jutia Group
Merck & Co., Inc. Announces $434 Million Collaboration With Arvinas Over ...
Bidness ETC - Apr 8, 2015
Merck & Co., Inc. (NYSE:MRK) announced Tuesday its decision to join hands with a privately held biotech firm Arvinas LLC for expediting the development of novel therapeutics, taking advantage of Arvinas' proteolysis-targeting chimera (PROTAC ...
Merck & Co. Inc. (NYSE:MRK) Releases A Strategic Alliances In Which Arvinas ... - StreetWise Report
Merck & Co., Inc. (NYSE:MRK) Ties Up With ArvinasFor A $434 Million Multi ... - USMarketsDaily (blog)
Merck & Co. Inc. (MRK) Closes 0.05% Up on the Day for April 22 - Apr 22, 2015
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move 0.05% to $57.69, representing a per-share move of $0.03, on volume of 7.89 million shares for Wednesday.
Merck & Co. Inc. (MRK) Closes 1.28% Up on the Day for April 20 - Apr 20, 2015
Merck & Co. Inc. currently has a total float of 2.83 billion shares and moves 12.18 million a day, on average. The stock opened at $57.50 on April 20 and traded between a low of $57.39 and a high of $58.00.
Morgan Stanley Awaits This Merck Data
Benzinga - Apr 21, 2015
In a report published Tuesday, Morgan Stanley analysts maintained an Equal-Weight rating on Merck & Co. (NYSE: MRK), saying that the company is filing in select patients in lung cancer earlier than expected, but its best to wait for survival data ...
Merck & Co. Inc. (MRK) Among Biggest DJIA Losers on April 16 - Apr 16, 2015
Shares of Merck & Co. Inc. led all laggers on the Dow Thursday with a decline of 1.04%. The DJIA closed at 18,105.80, which is a -0.04% change from the previous day's close.
Merck & Co. Inc. (MRK) Closes 1.04% Down on the Day for April 16 - Apr 16, 2015
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move -1.04% to $57.84, representing a per-share move of $0.61, on volume of 6.36 million shares for Thursday.
Company Update: Merck & Co Inc (NYSE:MRK) - Merck Reaffirms Continued ...
Jutia Group - Apr 21, 2015
Merck & Co Inc (NYSE:MRK) [Business Wire] - Merck , known as MSD outside the United States and Canada, today reaffirmed its longstanding commitment to discovering and developing novel medicines in the global fight against infectious diseases, ...
Merck Reaffirms Continued Commitment to Developing Innovative Medicines for ... - MarketWatch
Merck & Co HCV Entry To Significantly Affect Gilead Sciences, Inc. (GILD ...
Bidness ETC - Apr 8, 2015
In a research note published on Wednesday, Deutsche Bank expressed its concerns over Merck & Co., Inc. (NYSE:MRK) market entry in Hepatitis C Virus (HCV) treatment, triggering pricing competition and affecting market shares of Gilead Sciences, Inc.
Is Merck & Co. A Real Threat To Gilead Sciences & AbbVie Inc? - CNA Finance (press release)
Opposing Views on Gilead Hepatitis C Presentation - 24/7 Wall St.